Health
Gene Therapy for Kids’ Deadly Muscle Disease Fails to Reach Trial Goal
- Swiss drugmaker falls to lowest level in almost five years
- Companies argue other measures show the therapy works
While patients in the trial improved in an ambulatory assessment, the change wasn’t great enough to hit its primary endpoint, Sarepta said Monday in a statement.
Photographer: James MacDonald/BloombergThis article is for subscribers only.
Sarepta Therapeutics Inc. and Roche Holding AG slumped after the partners’ trial of a gene therapy for Duchenne muscular dystrophy failed to meet the main goal of a study, raising doubts that the treatment will be expanded to older children.
Sarepta shares sank as much as 49% on Tuesday in New York trading, the biggest drop since January 2021. Roche fell as much as 4.1% in Zurich trading to hit the lowest intraday level in five years.